In October 2024, Tarsus Pharmaceuticals (NASDAQ: TARS ), just over a year into the launch of its eyedrop, Xdemvy (lotilaner) for Demodex blepharitis ( DB ), announced it would be running a direct-to-consumer (DTC) TV campaign to market the drug. Such an aggressiveScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment ad ...